LC28-0126 clinical trials
Also written LC28-0126.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses LC28-0126 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses LC28-0126 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.CompletedPhase 1LG ChemNCT03196804Written as LC28-0126How we know
- Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI PatientsStatus unknownPhase 2LG Life SciencesNCT02770664Written as LC28-0126 Dose AHow we know
- Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI PatientsCompletedPhase 2LG Life SciencesNCT02070471Written as LC28-0126 Dose AHow we know
- Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male SubjectsCompletedPhase 1LG Life SciencesNCT01737424Written as LC28-0126How we know